New trial
Pilot Study: Proton SBRT for Complex Spinal Metastases
- Trial ID
- NCT06895564 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Published in
- New in Oncology - May 14, 2025
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is evaluating proton stereotactic body radiotherapy for nonhematologic spinal metastases in patients with complex lesions that cannot be effectively treated with standard photon SBRT, using a prescription dose of 30 Gy in 5 fractions.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings